Stefan Lethagen
Overview
Explore the profile of Stefan Lethagen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Konigs C, Meeks S, Nolan B, Schmidt A, Lofqvist M, Dumont J, et al.
Ther Adv Hematol
. 2024 Nov;
15:20406207241300809.
PMID: 39583653
Background: Immune tolerance induction (ITI) is the gold standard for inhibitor eradication to restore the clinical efficacy of factor replacement therapy in haemophilia. However, as ITI often requires frequent administration...
2.
Oldenburg J, Hay C, Peyvandi F, Tagliaferri A, Holme P, Alvarez-Roman M, et al.
Eur J Haematol
. 2024 Oct;
114(2):248-257.
PMID: 39434416
Objectives: The 24-month, prospective, non-interventional, European multicenter A-SURE study evaluated the real-world effectiveness of prophylaxis using an extended half-life recombinant factor VIII (FVIII) Fc fusion protein, efmoroctocog alfa (hereinafter rFVIIIFc),...
3.
Konkle B, Oldenburg J, Pasi J, Kulkarni R, Nolan B, Mahlangu J, et al.
Res Pract Thromb Haemost
. 2023 Sep;
7(6):102180.
PMID: 37753224
Background: Recurrent joint bleeds are a major cause of morbidity in severe hemophilia. Prophylaxis with efmoroctocog alfa (a recombinant factor VIII Fc fusion protein, [rFVIIIFc]) has demonstrated benefits beyond bleed...
4.
Steen Carlsson K, Winding B, Astermark J, Baghaei F, Brodin E, Funding E, et al.
Res Pract Thromb Haemost
. 2023 Mar;
7(2):100061.
PMID: 36908766
Background: Pain is a common feature of hemophilia, but prevalence of depression and anxiety is less studied. Registry data on prescription drugs can provide an objective measure of the magnitude...
5.
Shapiro A, Kulkarni R, Ragni M, Chambost H, Mahlangu J, Oldenburg J, et al.
Blood Adv
. 2023 Feb;
7(13):3049-3057.
PMID: 36848635
Long-term efficacy and safety of the extended half-life recombinant factor IX Fc fusion protein (rFIXFc) has been established among previously treated patients with severe hemophilia B in 2 phase 3...
6.
Malec L, Van Damme A, Chan A, Spasova M, Jain N, Sensinger C, et al.
Blood
. 2023 Feb;
141(16):1982-1989.
PMID: 36735911
Inhibitor development remains a major challenge in factor VIII (FVIII) replacement therapy. verITI-8 is the first prospective study of a recombinant FVIII Fc fusion protein (rFVIIIFc; efmoroctocog alfa) for first-time...
7.
Chowdary P, Holmstrom M, Mahlangu J, Ozelo M, Pabinger I, Pasi K, et al.
Res Pract Thromb Haemost
. 2022 Aug;
6(5):e12760.
PMID: 35910942
Background: Surgical procedures impose hemostatic risk to people with hemophilia, which may be minimized by optimal factor (F) replacement therapy. Methods: This analysis evaluates the efficacy and safety of extended...
8.
Steen Carlsson K, Winding B, Astermark J, Baghaei F, Brodin E, Funding E, et al.
Haemophilia
. 2022 Apr;
28(4):557-567.
PMID: 35460313
Introduction: People with haemophilia (PwH) may experience symptoms of haemophilia-related pain, depression or anxiety, which can negatively impact health-related quality of life. Aim: To obtain the perspective of PwH and...
9.
Berntorp E, LeBeau P, Ragni M, Borhany M, Abajas Y, Tarantino M, et al.
Haemophilia
. 2022 Mar;
28(3):453-461.
PMID: 35263495
Introduction: The B-Natural study is a multicentre, multinational, observational study of haemophilia B (HB) designed to increase understanding of clinical manifestations, treatment and quality of life (QoL). Aim: To characterise...
10.
Horneff R, Bystricka L, Santagostino E, Lethagen S, Casiano S
Semin Thromb Hemost
. 2021 Nov;
48(2):251-252.
PMID: 34749400
No abstract available.